Literature DB >> 20738309

Common occurrence of monoclonal B-cell lymphocytosis among members of high-risk CLL families.

Lynn R Goldin1, Mark C Lanasa, Susan L Slager, James R Cerhan, Celine M Vachon, Sara S Strom, Nicola J Camp, Logan G Spector, Jose F Leis, Vicki A Morrison, Martha Glenn, Kari G Rabe, Sara J Achenbach, Sallie D Algood, Fatima Abbasi, Laura Fontaine, Michelle Yau, Laura Z Rassenti, Neil E Kay, Timothy G Call, Curtis A Hanson, J Brice Weinberg, Gerald E Marti, Neil E Caporaso.   

Abstract

Monoclonal B-cell lymphocytosis (MBL) is an asymptomatic haematological condition characterized by low absolute levels of B-cell clones with a surface immunophenotype similar to that of chronic lymphocytic leukaemia (CLL). In the general population, MBL increases with age with a prevalence of 5-9% in individuals over age 60 years. It has been reported to be higher among first-degree relatives from CLL families. We report results of multi-parameter flow cytometry among 505 first-degree relatives with no personal history of lymphoproliferative disease from 140 families having at least two cases of CLL. Seventeen percent of relatives had MBL. Age was the most important determinant where the probability for developing MBL by age 90 years was 61%. MBL clustered in certain families but clustering was independent of the number of known CLL cases in a family. As is the case with CLL, males had a significantly higher risk for MBL than did females (P = 0·04). MBL patients had significantly higher mean absolute lymphocyte counts (2·4 × 10(9) /l) and B-cell counts (0·53 × 10(9) /l) than those with a normal B-cell immuno-phenotype. Our findings show that MBL occurs at a very high rate in high risk CLL families. Both the age and gender distribution of MBL are parallel to CLL, implying a shared inherited risk. Published 2010. This article is a US Government work and is in the public domain in the USA.

Entities:  

Mesh:

Year:  2010        PMID: 20738309      PMCID: PMC2966536          DOI: 10.1111/j.1365-2141.2010.08339.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  21 in total

1.  Monoclonal CD5+ and CD5- B-lymphocyte expansions are frequent in the peripheral blood of the elderly.

Authors:  Paolo Ghia; Giuseppina Prato; Cristina Scielzo; Stefania Stella; Massimo Geuna; Giuseppe Guida; Federico Caligaris-Cappio
Journal:  Blood       Date:  2003-11-20       Impact factor: 22.113

Review 2.  Monoclonal B-cell lymphocytosis (MBL): biology, natural history and clinical management.

Authors:  T D Shanafelt; P Ghia; M C Lanasa; O Landgren; A C Rawstron
Journal:  Leukemia       Date:  2010-01-21       Impact factor: 11.528

3.  Monoclonal B-cell lymphocytosis in first-degree relatives of patients with sporadic (non-familial) chronic lymphocytic leukaemia.

Authors:  Daniel M Matos; Sebastião J Ismael; Carlos A Scrideli; Fábio M de Oliveira; Eduardo M Rego; Roberto P Falcão
Journal:  Br J Haematol       Date:  2009-08-25       Impact factor: 6.998

4.  National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment.

Authors:  B D Cheson; J M Bennett; M Grever; N Kay; M J Keating; S O'Brien; K R Rai
Journal:  Blood       Date:  1996-06-15       Impact factor: 22.113

Review 5.  Diagnostic criteria for monoclonal B-cell lymphocytosis.

Authors:  Gerald E Marti; Andy C Rawstron; Paolo Ghia; Peter Hillmen; Richard S Houlston; Neil Kay; Thérèse A Schleinitz; Neil Caporaso
Journal:  Br J Haematol       Date:  2005-08       Impact factor: 6.998

6.  B-cell monoclonal lymphocytosis and B-cell abnormalities in the setting of familial B-cell chronic lymphocytic leukemia.

Authors:  Gerald E Marti; Patricia Carter; Fatima Abbasi; Glennelle C Washington; Nisha Jain; Vincent E Zenger; Naoko Ishibe; Lynn Goldin; Laura Fontaine; Nancy Weissman; Maria Sgambati; Guy Fauget; Pablo Bertin; Robert F Vogt; Barbara Slade; Philip D Noguchi; M A Stetler-Stevenson; Neil Caporaso
Journal:  Cytometry B Clin Cytom       Date:  2003-03       Impact factor: 3.058

7.  Inherited predisposition to CLL is detectable as subclinical monoclonal B-lymphocyte expansion.

Authors:  Andy C Rawstron; Martin R Yuille; Julie Fuller; Matthew Cullen; Ben Kennedy; Stephen J Richards; Andrew S Jack; Estella Matutes; Daniel Catovsky; Peter Hillmen; Richard S Houlston
Journal:  Blood       Date:  2002-10-01       Impact factor: 22.113

8.  Clinical progression and outcome of patients with monoclonal B-cell lymphocytosis.

Authors:  Sarah S Fung; Kortney L Hillier; Chantal S Leger; Irwin Sandhu; Linda M Vickars; Paul F Galbraith; Charles H Li; Heather A Leitch
Journal:  Leuk Lymphoma       Date:  2007-06

9.  Brief report: natural history of individuals with clinically recognized monoclonal B-cell lymphocytosis compared with patients with Rai 0 chronic lymphocytic leukemia.

Authors:  Tait D Shanafelt; Neil E Kay; Kari G Rabe; Timothy G Call; Clive S Zent; Kami Maddocks; Greg Jenkins; Diane F Jelinek; William G Morice; Justin Boysen; Susan Schwager; Deborah Bowen; Susan L Slager; Curtis A Hanson
Journal:  J Clin Oncol       Date:  2009-07-20       Impact factor: 44.544

10.  Monoclonal B lymphocytes with the characteristics of "indolent" chronic lymphocytic leukemia are present in 3.5% of adults with normal blood counts.

Authors:  Andy C Rawstron; Michael J Green; Anita Kuzmicki; Ben Kennedy; James A L Fenton; Paul A S Evans; Sheila J M O'Connor; Stephen J Richards; Gareth J Morgan; Andrew S Jack; Peter Hillmen
Journal:  Blood       Date:  2002-07-15       Impact factor: 22.113

View more
  27 in total

Review 1.  Monoclonal B-cell lymphocytosis and early-stage chronic lymphocytic leukemia: diagnosis, natural history, and risk stratification.

Authors:  Paolo Strati; Tait D Shanafelt
Journal:  Blood       Date:  2015-06-11       Impact factor: 22.113

Review 2.  Monoclonal B cell lymphocytosis--what does it really mean?

Authors:  Andy C Rawstron
Journal:  Curr Hematol Malig Rep       Date:  2013-03       Impact factor: 3.952

Review 3.  Precursors to lymphoproliferative malignancies.

Authors:  Lynn R Goldin; Mary L McMaster; Neil E Caporaso
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2013-04       Impact factor: 4.254

4.  [Monoclonal gammopathy of undetermined significance and monoclonal B-lymphocytosis].

Authors:  K Hübel; M Hallek
Journal:  Internist (Berl)       Date:  2013-06       Impact factor: 0.743

5.  Follicular lymphoma-like B cells of uncertain significance (in situ follicular lymphoma) may infrequently progress, but precedes follicular lymphoma, is associated with other overt lymphomas and mimics follicular lymphoma in flow cytometric studies.

Authors:  Raju K Pillai; Urvashi Surti; Steven H Swerdlow
Journal:  Haematologica       Date:  2013-07-05       Impact factor: 9.941

6.  Combined somatic mutation and copy number analysis in the survival of familial CLL.

Authors:  Weiyin Zhou; Lynn Goldin; Mingyi Wang; Mary L McMaster; Kristine Jones; Laurie Burdett; Stephen J Chanock; Meredith Yeager; Michael Dean; Neil E Caporaso
Journal:  Br J Haematol       Date:  2018-04-24       Impact factor: 6.998

Review 7.  Monoclonal B cell lymphocytosis: clinical and population perspectives.

Authors:  Neil E Caporaso; Gerald E Marti; Ola Landgren; Elizabeth Azzato; J Brice Weinberg; Lynn Goldin; Tait Shanafelt
Journal:  Cytometry B Clin Cytom       Date:  2010       Impact factor: 3.058

Review 8.  Immunologic aspects of monoclonal B-cell lymphocytosis.

Authors:  Mark C Lanasa; J Brice Weinberg
Journal:  Immunol Res       Date:  2011-04       Impact factor: 2.829

9.  Genome-wide association study identifies a novel susceptibility locus at 6p21.3 among familial CLL.

Authors:  Susan L Slager; Kari G Rabe; Sara J Achenbach; Celine M Vachon; Lynn R Goldin; Sara S Strom; Mark C Lanasa; Logan G Spector; Laura Z Rassenti; Jose F Leis; Nicola J Camp; Martha Glenn; Neil E Kay; Julie M Cunningham; Curtis A Hanson; Gerald E Marti; J Brice Weinberg; Vicki A Morrison; Brian K Link; Timothy G Call; Neil E Caporaso; James R Cerhan
Journal:  Blood       Date:  2010-12-03       Impact factor: 22.113

Review 10.  Familial leukemias.

Authors:  Peter H Wiernik
Journal:  Curr Treat Options Oncol       Date:  2015-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.